Caribou Biosciences Q4 licensing revenue rises, net loss narrows

Reuters03-06
<a href="https://laohu8.com/S/CRBU">Caribou Biosciences</a> Q4 licensing revenue rises, net loss narrows

Overview

  • Biopharmaceutical company reported increased Q4 licensing revenue compared to last year

  • Company reduced R&D and G&A expenses due to pipeline prioritization, helping narrow net loss

  • Caribou advancing CAR-T cell therapy programs, engaging with FDA for trial designs

Outlook

  • Caribou expects ANTLER phase 1 follow-up data in 2026

  • Company plans to report CB-011 dose expansion data in 2026

  • Caribou anticipates cash reserves to fund operations into 2H 2027

Result Drivers

  • LICENSING REVENUE - Increase driven by prior licenses of intellectual property to third parties

  • R&D EXPENSES - Decrease due to workforce reduction and strategic pipeline prioritization

Company press release: ID:nGNX4rTKX3

Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Licensing and Collaboration Revenue

$3.94 mln

Q4 Net Income

-$26.49 mln

Q4 Basic EPS

-$0.28

Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy"

  • Wall Street's median 12-month price target for Caribou Biosciences Inc is $9.00, about 400% above its March 4 closing price of $1.80

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment